Founded in 1999 in Copenhagen, Denmark, Genmab A/S is an international biotechnology company specializing in differentiated antibody therapeutics for the treatment of cancer and other serious diseases. Headquartered in Copenhagen, the company has built a strong global platform spanning Europe, North America, and Asia-Pacific, supported by a proprietary antibody technology base and a growing commercial presence. Genmab’s science powers eight approved antibody medicines, and the company continues to advance a substantial late-stage pipeline while expanding its international reach. In 2025, Genmab reported revenue of USD 3.72 billion and had 2,682 full-time equivalent employees at year-end, reflecting the scale and momentum of one of Europe’s most successful biotechnology companies.
Updated 2026-03-19